Form 4: Veracyte Executive Phillip G. Febbo Reports Stock Transaction for Tax Obligations

Phillip G. Febbo, Chief Scientific & Medical Officer at Veracyte, Inc., reported a transaction involving the withholding of 6,738 common stock shares to cover tax obligations related to vesting restricted stock units.

Summary

• Phillip G. Febbo, the Chief Scientific & Medical Officer of Veracyte, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction on December 2, 2024, where 6,738 shares of common stock were withheld.
• This withholding was to satisfy tax obligations related to the vesting of 13,295 Restricted Stock Units (RSUs) granted on October 2, 2023.
• The transaction is not a sale by Mr. Febbo but rather a transfer to cover taxes.
• Following the transaction, Mr. Febbo beneficially owns 86,348 shares of Veracyte common stock.

Sentiment

Score: 7

Explanation: The document is a routine filing related to executive stock transactions, which is neither positive nor negative for the company's overall performance. It is a neutral event.

Industry Context

This is a routine filing related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders in the US.
• The transaction is typical for executives receiving stock-based compensation, where a portion of shares are withheld to cover taxes upon vesting.
• Similar transactions are regularly reported by executives at comparable companies.

Stakeholder Impact

• The transaction has a neutral impact on shareholders as it is a standard procedure for executive compensation.
• The transaction does not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, SEC, Veracyte, Phillip G. Febbo, stock transaction, restricted stock units, tax withholding, beneficial ownership